8-K: Greenland Mines Emerges, Pivoting to Global Mining

Klotho Neurosciences rebrands to Greenland Mines Ltd, shifts focus to natural resources while retaining biotech division.

Summary

• Klotho Neurosciences, Inc. has officially changed its corporate name to Greenland Mines Ltd, effective March 11, 2026, at 5:00 PM.
• The company's stock ticker symbol on the Nasdaq Capital Market changed from KLTO to GRML, effective at market open on March 12, 2026.
• The name change was effectuated through a merger of GML Subsidiary Corp. into Klotho Neurosciences, Inc., with the latter surviving and amending its Certificate of Incorporation.
• Greenland Mines Ltd now operates with two divisions: Natural Resources and Cell and Gene Therapy.
• The Natural Resources division focuses on the exploration and development of the Skaergaard Project in Southeast Greenland, acquired through Greenland Mines Corp.
• The Skaergaard Project is described as one of the largest undeveloped palladium, gold, and platinum deposits globally.
• It holds a 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq.
• The project has a gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices.
• The Cell and Gene Therapy division continues to include Klotho's KLTO-202 primary indication for ALS.
• An investor webcast was scheduled for March 12, 2026, at 4:15 PM ET to discuss the strategic rationale of the acquisition and benefits for shareholders.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a strategically significant move, diversifying the company into a high-value natural resources sector with a substantial asset, while retaining its biotech interests. This pivot offers new growth avenues but also introduces new operational and market risks.

Positives

• Acquisition of an 80% interest in the Skaergaard Project, a significant natural resource asset with an option to acquire the remaining 20%.
• The Skaergaard Project boasts a substantial 2022 NI 43-101 Indicated and Inferred Mineral Resource of 25.4 Moz PdEq and 23.5 Moz AuEq.
• The project's gross undiscounted in-situ resource value is estimated at approximately $68 billion, indicating significant potential.
• The company retains its Cell and Gene Therapy division, including the KLTO-202 program for ALS, allowing for diversification.
• The management team is described as experienced in mining, geological, biotech, and capital markets.

Risks

• Inability to implement business plans effectively.
• Failure to identify and realize additional opportunities.
• Inability to meet or exceed financial projections.
• Changes in the regulatory or competitive environment in which the company operates.
• Mineral Resources are not Mineral Reserves and do not have demonstrated economic viability.
• Gross undiscounted in-situ metal values are illustrative calculations and do not account for mining recoveries, metallurgical losses, capital costs, operating costs, royalties, taxes, permitting requirements, or other technical/economic factors.
• These illustrative values are not indicative of future revenue, project economics, or net present value.
• No preliminary economic assessment, pre-feasibility study, or feasibility study has been completed on the Skaergaard Project.
• There is no certainty that the Mineral Resources disclosed will be converted to Mineral Reserves or that an economically viable mining operation can be established.

Future Outlook

The company's forward-looking statements describe future commercial operations and are subject to risks and uncertainties, including the ability to implement business plans, identify and realize additional opportunities, or meet financial projections. The company undertakes no obligation to update these statements except as required by law.

Management Comments

• The company announced its corporate name change to Greenland Mines Ltd and its stock ticker to GRML, effective at market open on March 12, 2026.
• Existing shareholders will not be required to take any action as shares held in brokerage accounts will be automatically updated.
• An investor webcast was scheduled to discuss the strategic rationale of the recent acquisition and benefits for shareholders.

Industry Context

StockSavvy.ai notes a significant strategic pivot and diversification for the company, moving from a primary focus on neuroscience to a diversified entity with a substantial natural resources division. This shift could attract a new investor base interested in mining assets while retaining exposure to biotech. The acquisition of the Skaergaard Project positions the company in the global palladium, gold, and platinum market, a sector distinct from its original biotech focus.

Comparison to Industry Standards

• The Skaergaard Project is described as 'one of the largest undeveloped palladium, gold, and platinum deposits in the world,' suggesting a potentially world-class asset.
• The project's gross undiscounted in-situ resource value of approximately $68 billion based on February 2026 metal prices highlights its significant scale, though this is an illustrative calculation and not an economic valuation.

Corporate Governance

Stakeholder Impact

• Shareholders: Shares will automatically update to the new ticker symbol GRML, reflecting the company's new identity and diversified business model. This fundamental change may attract new investors and alter the existing shareholder base's investment thesis.
• Employees: The company is now a diversified entity with operations in both natural resources and cell and gene therapy, potentially impacting roles and organizational structure.
• Customers/Partners: For the biotech division, existing relationships may continue, while the natural resources division will establish new partnerships related to mining exploration and development.

Next Steps

• The company held an investor webcast on March 12, 2026, to discuss the strategic rationale of its recent acquisition and benefits for shareholders.

Key Dates

Keywords

Greenland Mines Ltd, GRML, Klotho Neurosciences, KLTO, Skaergaard Project, Palladium, Gold, Platinum, Mineral Resources, Mining, Natural Resources, Cell and Gene Therapy, ALS, Corporate Rebranding, Ticker Change, SEC 8-K, Delaware General Corporation Law